Shire gains a de­layed FDA OK for ‘block­buster’ dry eye drug li­fite­grast

Nine months af­ter the FDA hand­ed Shire $SH­PG a re­jec­tion for its dry eye drug li­fite­grast, the biotech com­pa­ny says it’s bounced back with a de­layed ap­proval from the FDA. And now Shire will set out to see if it can achieve its ear­li­er fore­cast of more than a bil­lion dol­lars in an­nu­al sales.

Shire will be tack­ling a broad mar­ket in­clud­ing more than 16 mil­lion peo­ple who have been di­ag­nosed with dry eye dis­ease. The com­pa­ny plans to get start­ed mar­ket­ing the eye drop ther­a­py in a few months, sell­ing it as Xi­idra.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.